Statins have low risk of side effects

December 10, 2018

DALLAS, Dec. 10, 2018 -- The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs. It is published in the Association's journal Circulation: Arteriosclerosis, Thrombosis and Vascular Biology.

According to the statement, one in four Americans over the age of 40 takes a statin drug, but up to 10 percent of people in the United States stop taking them because they experience symptoms that they may assume are due to the drug, but may not be.

"In most cases, you should not stop taking your statin medication if you think you are having side effects from the drug - instead, talk to your healthcare provider about your concerns. Stopping a statin can significantly increase the risk of a heart attack or stroke caused by a blocked artery," said Mark Creager, M.D., former president of the American Heart Association and director of the Heart and Vascular Center at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire.

The one exception is if you suddenly begin to pass dark urine, which can be a sign of a very rare problem in which serious muscle injury, called rhabdomyolysis, can result in acute kidney failure. If you see this sign, you should stop your statin and call your healthcare provider immediately. The current review of research included in this statement shows that rhabdomyolysis was seen in less than 0.1 percent of patients on statin therapy.

The most common side effects that patients report are muscle aches and pains. Analyses of multiple double-blind randomized controlled studies of all currently available statins -

at up to maximum recommended doses - have shown that no more than one percent of patients develop muscle symptoms that are likely caused by statin drugs.

While many statin-treated patients do attribute any muscle symptoms they develop to their statins, muscle aches and pains are common among middle aged and older adults and have many causes. Because patients may be uncertain about the cause of these symptoms, and because the patient's belief that their symptoms are caused by their statins could prompt them to stop taking them, elevating their risk for a cardiovascular event, healthcare providers should pay close attention to their patients' concerns and help them assess likely causes.

If there is uncertainty, healthcare providers should consider measuring a patient's creatinine kinase levels, a marker in the blood that could indicate muscle damage. If the creatine kinase levels are normal, the patient may be reassured that muscle damage has not occurred. Not having enough Vitamin D can also cause muscle aches and pains and its levels can be easily measured.

There is another reason that people who are being treated with statins may experience muscle pain - the "nocebo effect" - the expectation of harm from the therapy based on reporting of muscle problems attributed to statins in the press, warnings provided by healthcare providers and in drug package inserts.

Symptoms related to the "nocebo effect" can be severe, and they should never be dismissed by the clinician. The statement suggests trying a lower dose of the same statin drug or trying a different statin drug to see if the patient's symptoms improve. Even so, teasing out the reasons a patient is experiencing symptoms can be difficult.

Statin therapy may slightly increase the risk of diabetes, especially in people who already have risk factors for it, such as a sedentary lifestyle and obesity. However, the absolute risk of new patients being diagnosed with diabetes due to statin use in major trials has been only about 0.2 percent per year.

For people who already have diabetes the average increase in HbA1c (a measurement of how much glucose is in the blood) when taking statins is small and not considered a reason not to prescribe these agents. While diabetes is a major risk factor for heart attacks, heart failure and other cardiovascular events, statin therapy substantially reduces the risk of such events and may be appropriate for patients who already have diabetes.

Although the statement notes no increased risk of a first hemorrhagic stroke with statin use, there may be a slightly increased risk of a hemorrhagic stroke in people who have already had that type of stroke (caused by a rupture in an artery). However, the absolute risk is very small and the benefit in reducing overall stroke and other vascular events generally outweighs that risk.

The authors also reviewed the scientific evidence on other possible statin side effects and safety concerns including liver damage, neurological effects, peripheral neuropathy, cataracts, tendon ruptures and others but found little evidence that statins were associated with a greater risk of these conditions.

Statin drugs work to lower the amount of low-density lipoprotein (LDL) cholesterol - known as "bad" cholesterol produced by the liver. There are many different statins available in the United States, including low-cost generic versions. To determine if statins are appropriate for a patient, the American Heart Association recommends that patients work with their healthcare provider to evaluate the risk of having a heart attack or stroke in the next ten years, using the American Heart Association/American College of Cardiology Risk Calculator.

Depending on a patient's risk score, the patient and healthcare provider should discuss ways to lower it if it is elevated, including lifestyle and diet changes. Statin therapy might be appropriate for you if you fall into one of the following groups:
-end-
Co-authors are Connie B. Newman, M.D., Chair; Terry A. Jacobson M.D.; Vice-Chair; David Preiss F.R.C. Path. Ph.D.; Jonathan A. Tobert M.D., Ph.D.; Robert L. Page II, Pharm.D.; M.S.PH.; Larry B. Goldstein, M.D., Clifford Chin, M.D.; Lisa R. Tannock. M.D.; Michael Miller, M.D.; Geetha Raghuveer, M.D., M.P.H.; P. Barton Duell, M.D.; Eliot A. Brinton, M.D.; Amy Pollak, M.D.; Lynne T. Braun, Ph.D.; and Francine K. Welty, M.D., Ph.D.

Additional Resources:

The Association receives funding primarily from individuals. Foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https://www.heart.org/en/about-us/aha-financial-information.

About the American Heart Association

The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.

American Heart Association

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.